Introduction: Understanding the relationship between subsequent-line therapies and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Objective: In this post hoc analysis, we investigated OS in lenvatinib-and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up period. Methods: The follow-up period commenced at the first offtreatment visit after stopping the study medication and continued until study termination,
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with about 841,000 diagnoses and 782,000 deaths per year [1] . It is the most common form of liver cancer and is primarily associated with chronic infections by hepatitis B and C viruses. In 2015, 257 million people worldwide were reported as having the hepatitis B virus and 71 million people had the hepatitis C virus [2] . These viruses often lead to cirrhosis, which limits treatment options for HCC [3, 4] . Initially, sorafenib was the only first-line systemic therapy that improved overall survival (OS) for unresectable HCC (uHCC) [4, 5] , until the recent (2018) approval of lenvatinib [6, 7] . Lenvatinib is an oral multikinase inhibitor targeting both vascular endothelial growth factor receptors 1-3 and fibroblast growth factor receptors 1-4, in addition to platelet-derived growth factor receptor α, RET, and KIT [8] [9] [10] [11] .
REFLECT was a randomized, open-label, phase 3 study that compared the efficacy and safety of lenvatinib versus sorafenib in first-line treatment of patients with uHCC [6] . Lenvatinib demonstrated a treatment effect on OS, statistically confirmed by noninferiority to sorafenib (the primary end point of median OS was 13.6 vs. 12.3 months; hazard ratio [HR] 0.92; 95% CI 0.79-1.06) [6] . Lenvatinib resulted in statistically significant improvements in the secondary end points of progression-free survival (PFS), time to progression, and objective response rate (ORR) versus sorafenib (tested sequentially) [6] . Based on the outcomes from REFLECT, lenvatinib became the first agent approved in the first-line treatment setting for uHCC in over a decade [6] .
The recent availability of new treatment options in first-and subsequent-line therapies has shifted the treatment paradigm for HCC, resulting in questions regarding appropriate medication choices and the timing and sequencing of anticancer therapies. There are relatively few studies directly examining the relationship between OS and subsequent-line therapies [12] [13] [14] [15] [16] [17] .
Understanding the relationship between subsequent-line therapies and OS is important for maximizing OS for patients with HCC. Therefore, in this post hoc analysis, we evaluated OS following first-line treatment with lenvatinib or sorafenib in patients with uHCC from REFLECT who received subsequent anticancer medication during the survival follow-up period. We also assessed the subset of patients who responded to lenvatinib or sorafenib during REFLECT, and subsequently received other systemic anticancer medication(s).
Patients
Briefly, eligible patients were ≥18 years of age and had histologically or cytologically uHCC with 1 or more measurable target lesions. Patients had Barcelona Clinic Liver Cancer stage B or C, Child-Pugh class A, and an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. Controlled blood pressure (≤150/90 mm Hg) and adequate liver, bone marrow, blood, renal, and pancreatic functions were required. Exclusion criteria included 50% or higher liver occupation, clear bile duct invasion, invasion at the main portal vein (Vp4), or previous systemic therapy for HCC. Full patient eligibility criteria were previously published [6] .
This study (NCT01761266) was conducted in accordance with the Declaration of Helsinki, all relevant Institutional Review Boards, and local laws. All patients provided written informed consent.
Study Design and Treatment
REFLECT was a phase 3, multicenter, randomized, open-label, noninferiority study comparing lenvatinib to sorafenib in patients with uHCC [6] . Patients were randomized 1: 1 to receive either lenvatinib or sorafenib [6] . Treatment cycles were 28 days in length. Lenvatinib (Eisai Inc., Woodcliff Lake, NJ, USA) was administered orally once daily at a dosage of either 12 mg/day (for baseline patient bodyweight ≥60 kg) or 8 mg/day (for baseline patient bodyweight < 60 kg). In the case of lenvatinib-related adverse events, the dose could be reduced by increments of 4 mg to a minimum dosage of 4 mg every other day. Sorafenib (Bayer, Leverkusen, Germany) 400 mg was administered orally twice daily. Modifications to sorafenib dosages were allowed based on regional prescribing information [6] .
First-line treatment continued until disease progression, intolerable adverse events, or withdrawal of consent. The study follow-up period commenced at the first off-treatment visit (within 30 days of discontinuing the study drug for any reason) and continued until sponsor study termination, withdrawal of consent, or death [6] . All poststudy systemic anticancer therapies were reported until death or data cutoff (November 13, 2016) and were captured as part of the survival follow-up period.
Study Objectives
The primary end point was OS, as measured from randomization to patient death from any cause. Patients remaining alive at the end of the study were censored at data cutoff [6] . Secondary end points were PFS, time to progression, ORR, quality-of-life measurements, and plasma pharmacokinetics for lenvatinib [6] . These end points have previously been reported [6] .
Post Hoc Subgroup Analyses
In this post hoc analysis, we investigated OS in lenvatinib-and sorafenib-treated patients from REFLECT who received subsequent anticancer medication during the survival follow-up period.
Patients who received nonsystemic subsequent anticancer treatments (e.g., transcatheter arterial chemoembolization) during the survival follow-up period were not excluded from the analysis. All patients who received subsequent systemic anticancer medication during the survival follow-up period were counted in the analysis as patients who received subsequent systemic medication, regardless of other treatments received. All other patients were counted in the analysis as patients who did not receive subsequent systemic anticancer medication. We also investigated the subset of patients who responded to lenvatinib or sorafenib during REFLECT, and subsequently received anticancer medication (includes patients who continued first-line medication and those who transitioned to a different medication) during the follow-up period. Responders were defined as patients who achieved either complete or partial tumor response as assessed by investigators in accordance with modified Response Evaluation Criteria In Solid Tumors (mRECIST), which do not require confirmation of response for randomized trials where ORR is not the primary end point [18] . Safety and tolerability data were not collected during the survival followup period.
Statistical Methods
Analyses were conducted for the subgroup of REFLECT patients who received subsequent anticancer medication. The HRs for OS were calculated using the Cochran-Mantel-Haenszel method, stratified by interactive response system stratification factors (region, macroscopic portal vein invasion, and ECOG PS) and are presented with 2-sided 95% CI. Evaluations were performed using SAS version 9 or higher. 
Results

Subsequent Anticancer Medication(s) and Patient Status
Patient dispositions in REFLECT have been previously published [6] . A total of 340 patients were included in this post hoc subgroup analysis.
Of the 954 patients randomized to receive first-line lenvatinib (n = 478) or sorafenib (n = 476) in REFLECT, 340 received subsequent anticancer medication during the survival follow-up period: 156 (32.6%) had received first-line lenvatinib and 184 (38.7%) had received first-line sorafenib ( Table 1) . Of the patients who received subsequent anticancer medication, 60 who were randomized to first-line lenvatinib and 63 who were randomized to first-line sorafenib also received subsequent anticancer procedures (excluding radiotherapy). Of the patients who were treated with first-line lenvatinib, the most common subsequent anticancer medication was sorafenib (25.3%; Table 1 ). Of the patients treated with first-line sorafenib, the most common subsequent anticancer medication beyond radiographic progression was also sorafenib (11.8%; Table 1 ).
The biggest disparity between the first-line lenvatinib and first-line sorafenib groups was the number of patients enrolled in second-line clinical trials and randomized to subsequent investigational drugs or placebo: 3.1% of those who had received first-line lenvatinib versus 9.5% of those who had received first-line sorafenib ( Table 1 ). The specific classes of these agents are unknown.
ECOG PS, Child-Pugh class, and liver function assessments for lenvatinib-and sorafenibtreated patients at the time of treatment discontinuation were similar between treatments ( Table 2) .
OS for the REFLECT Population
Patients in REFLECT randomized to first-line lenvatinib had a median OS of 13.6 months (95% CI 12.1-14.9); patients randomized to first-line sorafenib had a median OS of 12.3 months (95% CI 10.4-13.9 months; Table 3 ; Fig. 1, 2a ) [6] . These data were previously published in Kudo et al. [6] . 
OS for First-Line Treatment Responders
First-line lenvatinib responders who received any subsequent anticancer medication (n = 43) had a median OS of 25.7 months (95% CI 18.5-34.6; Table 3 ; Fig. 3a ). First-line sorafenib responders who received any subsequent anticancer medication (n = 16) had a median OS of 22.3 months (95% CI 14.6-not evaluable; Table 3 ; Fig. 3b ). Lenvatinib responders who received subsequent sorafenib treatment (n = 35) had a median OS of 26.2 months (95% CI 18.2-34.6; Fig. 4 ). Only 8 sorafenib responders received poststudy sorafenib treatment; therefore, survival estimates were not performed for this subgroup.
Discussion
The impact of the multiple recent approvals in the treatment of advanced HCC is challenging our assumptions on survival in the first-line setting. In REFLECT, lenvatinib had a positive effect on OS and was statistically confirmed to be noninferior to sorafenib, but did not show superiority despite its significant improvements in PFS, ORR, and time to progression [6] . Per investigator review using mRECIST, the ORR for lenvatinib was 24.1 vs. 9.2% for sorafenib [6] . A recent (2019) multivariate analysis by Kudo et al. [19] of REFLECT responders demonstrated a correlation between objective response and OS, similar to analyses from other large clinical trials in uHCC [20, 21] , both by independent review using mRECIST. This post hoc analysis, based on information captured in the survival follow-up period of REFLECT, adds additional support for investigating the importance of treatment sequence on OS. Approximately one-third of patients from both treatment arms in REFLECT received subsequent anticancer medication and at the time of treatment discontinuation, ECOG PS and liver function were similar for patients randomized to either treatment. Despite these similarities, in the subset of patients that received subsequent anticancer medication, patients randomized to first-line lenvatinib had numerically longer median OS than patients randomized to first-line sorafenib. While the number of first-line responders who received subsequent anticancer medication was too small to draw strong conclusions, those randomized to first-line lenvatinib also had longer median OS compared with those randomized to first-line sorafenib. Interestingly, both treatment arms had similar median OS for the overall population. However, there were more patients who received subsequent anticancer medication following first-line sorafenib (n = 184) than patients who received first-line lenvatinib (n = 156), and this imbalance may be the cause of the similar OS between treatment arms in the overall population. Regardless of first-line treatment, patients who received subsequent anticancer medication had longer median OS as compared with patients who did not receive subsequent medication.
At the time of the REFLECT study (study period March 1, 2013 -November 13, 2016 , currently common therapies such as regorafenib and nivolumab were in clinical trials requiring the failure of first-line sorafenib, which limited second-line investigational agent options for patients receiving first-line lenvatinib. Though approximately 3-fold more patients treated with first line sorafenib went on to participate in clinical trials with investigational drugs, patients randomized to first-line lenvatinib who received subsequent medication had numerically longer median OS. The majority of patients who received first-line lenvatinib and then subsequent anticancer medication received second-line sorafenib, which was the only systemic treatment at the time with demonstrated activity in HCC [6] . Therefore, the difference in OS between patients who received first-line lenvatinib or sorafenib followed by subsequent anticancer medication may be attenuated simply by the requirement for the failure of first-line sorafenib to enter into investigational trials.
With the recent approval of many second-line treatment options (regorafenib, nivolumab, pembrolizumab, cabozantinib, and ramucirumab) for uHCC [22, 23] , it is important to assess treatment patterns for patient benefit. There are many hurdles to getting a patient with uHCC to second-line treatment. Disease characteristics, such as ECOG status and poor liver function, can have a significant outcome on trial results, as they can decrease tolerance of the study medication and increase the incidence of AEs [24] .
The study of regorafenib after sorafenib in patients with HCC (RESORCE) was a phase 3 trial showing that patients with HCC who progressed on sorafenib and were then randomized to regorafenib had a median OS of 10.6 months (95% CI 9.1-12.1) compared with 7.8 months (6.3-8.8) for those then randomized to a placebo (NCT01774344 [25] ). However, patients who participated in RESORCE could not have any systemic treatments for HCC prior to sorafenib, and they must have tolerated sorafenib and only discontinued due to disease progression [25] . Additionally, they had to have a Child-Pugh Class A, an ECOG PS of 0 or 1, and a life expectancy of at least 3 months [25] . These criteria may have improved the chance of patients tolerating regorafenib, which then resulted in improved OS [24] .
The patient population of REFLECT was much more varied, yet the median survival for patients randomized to first-line lenvatinib followed by subsequent medication, especially for responders, is the highest reported to date in a phase III trial for uHCC. These data suggest that first-line lenvatinib followed by subsequent systemic anticancer medication could be an important treatment sequence that may lead to longer OS. This sequence may have even greater survival benefits for responders to first-line lenvatinib, though the proportion of responders who received subsequent anticancer medication was small compared with the overall REFLECT population. We also recognize that our post hoc analyses are limitedpatients were not prerandomized to the subsequent medications they received, and there could be selection bias confounding the results. Given the exploratory nature of these analyses, the results presented here are descriptive and should be interpreted with caution. 
